Potential Anti-Tumor Activity of Biguanides and Statins in Neuroendocrine Tumor Cells Abstract #1875

Introduction: Recent studies have suggested that biguanides and statins have beneficial effects on various cancer types; however, the precise effects and the molecular mechanisms underlying this pathophysiological association are still not well understood in neuroendocrine tumor (NETs).
Aim(s): To investigate the potential effects of different biguanides and statins on NETs.
Materials and methods: Proliferation, migration, secretion and gene expression in BON1/QGP1 cells.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Aura Dulcinea Herrera-Martínez
Keywords: NETs, biguanides, statins

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1908 Staging Classification Comparison of Resected Pancreatic Neuroendocrine Tumors (pNETs) Utilizing the National Cancer Database (NCDB)
Introduction: The staging classification of pNETs remains a matter of debate and no obvious superior system has emerged.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Gustavo Westin
#3053 The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors
Introduction: Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Ricardo Blázquez-Encinas
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features
Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Emilia Alors-Pérez
#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman